Captor Therapeutics (CTX) Q1 2025 earnings summary

Executive summary

• Report covers the three months ended March 31, 2025, with comparative data for Q1 2024.

• Operations focus on R&D in biotechnology, with continued losses as expected for early-stage drug development.

• Key events after the reporting period include the termination of a major collaboration and resolution of a grant dispute.

Financial highlights

• Consolidated Q1 2025 revenue from R&D services: PLN 2,606k, down from PLN 4,505k year-over-year.

• Net loss for Q1 2025: PLN -10,719k, compared to PLN -9,440k in Q1 2024.

• Earnings per share: PLN -1.95 (Q1 2025) vs. PLN -2.03 (Q1 2024).

• Cash and cash equivalents at March 31, 2025: PLN 16,624k, down from PLN 39,257k at year-end 2024.

• Net cash flow from operating activities: PLN 23,061k (Q1 2025) vs. PLN -10,253k (Q1 2024).

• Net cash outflow from investing activities: PLN -44,602k (Q1 2025).

Outlook and guidance

• Management expects continued operating losses due to the early stage of R&D projects.

• Additional funding sources, collaborations, and potential capital raises are being explored for ongoing development beyond 2025.

• Board is confident in the company’s ability to meet obligations for at least 12 months post-report.